Two-thirds of people living with HIV would like to try injectable treatment, according to European survey
Doravirine injections were safe and long-lasting, but did not reach therapeutic levels
Injectable PrEP offers superior efficacy to oral PrEP in clinical trial
Injectable antiretrovirals for HIV treatment or prevention: ambivalent views of potential users
Long-acting injectables might be administered every two months
Effectiveness and frequency of dosing are the most important factors affecting acceptability of injectable HIV therapy, says US study
Oral cabotegravir and rilpivirine still effective at 312 weeks
Ibalizumab monoclonal antibody is effective in real-world use
PrEP implant could last well over a year
